SAR 422459

Drug Profile

SAR 422459

Alternative Names: ATP-binding transporter gene therapy; SAR422459; Stargardt disease gene therapy - Oxford BioMedica/Sanofi; StarGen

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Developer Oxford BioMedica; Sanofi
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye-Disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stargardt disease

Most Recent Events

  • 16 Sep 2015 Phase-I/II development is ongoing for Stargardt disease 1 in USA and France (NCT01367444, NCT01736592)
  • 17 Oct 2013 Oxford BioMedica reaches an agreement with the US FDA and ANSM to resume recruitment into the phase I/IIa trial for Stargardt disease 1 in USA and France
  • 03 Jun 2013 Oxford BioMedica suspends enrolment in its phase I/II trial for Stargardt disease 1 in USA (NCT01367444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top